• 2021-05-20

[Huayu-Molecular Biology Laboratory] should adjust its operation mode in response to the COVID-19 epidemic.

• 2020-09-07

The company and Genya Biotechnology Co., Ltd. jointly developed a new drug for the treatment of lupus erythematosus, GV17, and submitted a pre-IND meeting application to the U.S. FDA

• 2020-09-03

[Huayu-Molecular Biology Laboratory] Announcement of the new version of the inspection form (v5).

• 2019-12-27

[Huayu-Molecular Biology Laboratory] Announcement of Submission Form (v4).

• 2019-12-01

Development and treatment of pan-neuromyelitis

• 2019-09-01

Imatinib blood concentration monitoring

• 2019-06-01

Tumor associated neurotic syndrome

• 2019-05-25

Adept Full-time anti-adhesion Expert Session

• 2019-04-16

The company was awarded the ISO 13485:2016 certificate by Taiwan Inspection Technology Co., Ltd

• 2019-03-01

Introduction and progress of anti-NMDA receptor encephalitis

• 2018-10-19

Haoyu joins hands with Huayu to enter the RFA 1.0/2.0 generation of radiofrequency ablation technology

• 2018-09-03

2018 DR-70 Health examination Dinner Lecture

• 2018-06-30

Treatment of methanol and ethylene glycol poisoning

• 2018-05-08

The Board of Directors of the Company has resolved to merge with Jianru Pharmaceutical Co., Ltd

• 2018-05-08

To play a one-stop effect, Huayu Pharmaceutical intends to merge with Jianru Pharmaceutical

• 2018-05-08

Huayu Pharmaceutical announced the merger with Jianru Pharma to accelerate the energy of pharmaceutical research and development